MUMBAI (Reuters) - Indian drug maker Eris Lifesciences Ltd's initial public offering of shares to raise up to 17 billion rupees ($270 million) was subscribed more than three times on the last day of the sale on Tuesday, stock exchange data showed.
The sale received bids for 52.4 million shares, or 3.29 times the 15.9 million shares on offer to the public, according to data from the National Stock Exchange as of 0100 GMT.
Shareholders in Eris including private equity firm ChrysCapital were selling a total 28.8 million shares in a price range of 600 rupees to 603 rupees each.
Anchor investors including Abu Dhabi Investment Authority bought 12.9 million shares as part of the IPO at 603 rupees apiece.
The stock is scheduled to make its trading debut on or around June 29.
Axis Capital, Citigroup and Credit Suisse were the banks on the IPO.
Central Depository Services (India) Ltd, whose up to $81 million IPO that closes on Wednesday, was subscribed 7.55 times by the second day of the sale.
(Reporting by Devidutta Tripathy; Editing by Biju Dwarakanath)
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app